Recall pneumonitis during systemic treatment with sunitinib
نویسندگان
چکیده
منابع مشابه
Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report
BACKGROUND The oral multi-kinase inhibitor sunitinib malate improves the survival of patients with gastrointestinal stromal tumors (GIST) after the disease progresses or intolerance to imatinib mesylate develops. Urinary fistulae arising during treatment with sunitinib for GIST have not been described. CASE PRESENTATION We describe a 62-year-old female patient diagnosed with unresectable GIST...
متن کاملIncidence of awareness with recall during general anesthesia
Background: Experience of awareness and recall during general anesthesia can be very distressing for patients. There is no doubt that surgery pain is the most distressing feature of awareness. This condition can cause neurosis in patients. If patient be aware during surgery and be able to hear some comment, she or he senses weakness, paralysis, feeling of helpless and anxiety, panic and death. ...
متن کاملRecall lung pneumonitis due to carmustine after radiotherapy.
A patient who developed pneumonitis immediately after the administration of carmustine (BCNU), within exactly the same field as previous irradiation, is presented. The patient responded partially to corticosteroids. This case suggests that irradiation causes subclinical sensitisation of the lung and can therefore have an additive effect in precipitating lung damage when another pulmonary toxin ...
متن کاملPneumonitis due to cytomegalovirus during chronic methotrexate treatment.
Although hypersensitivity pneumonitis is the most common pulmonary complication described during treatment with methotrexate, other complications like lymphoproliferative and infectious disease may be considered in the study of respiratory disease associated to methotrexate. The existence of an increased risk to developing infectious diseases may be similar to that observed during treatment wit...
متن کاملAbscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment
BACKGROUND Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of tyrosine kinase inhibitors, such as sunitinib. The molecular targets of sunitinib are receptor tyrosine kinases (RTKs). Moreover, sunitinib has an additional anti-angiogenic effect through its inhibition of the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2010
ISSN: 0923-7534
DOI: 10.1093/annonc/mdq444